Probiotics, Nuclear Receptor Signaling, and Anti-Inflammatory Pathways
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
There is increased investigation of the human microbiome as it relates to health and disease. Dysbiosis is implicated in various clinical conditions including inflammatory bowel disease (IBD). Probiotics have been explored as a potential treatment for IBD and other diseases. The mechanism of action for probiotics has yet to be fully elucidated. This paper discusses novel mechanisms of action for probiotics involving anti-inflammatory signaling pathways. We highlight recent progress in probiotics and nuclear receptor signaling, such as peroxisome-proliferator-activated receptor gamma (PPARγ) and vitamin D receptor (VDR). We also discuss future areas of investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach
Manichanh, C., Rigottier-Gois, L., Bonnaud, E., Gloux, K., Pelletier, E., Frangeul, L., Nalin, R., Jarrin, C., Chardon, P., Marteau, P., et al. (2006) · Gut · doi:10.1136/gut.2005.073817 · Cited by 2,277 · cited 1×
“Microbial composition in IBD patients with ulcerative colitis (UC) or Crohn’s disease (CD) as compared to unaffected individuals has been studied and shows decreased diversity [4, 14–19].”
BackgroundMetabolic Syndrome and Altered Gut Microbiota in Mice Lacking Toll-Like Receptor 5
Vijay-Kumar, M., Aitken, J. D., Carvalho, F. A., Cullender, T. C., Mwangi, S., Srinivasan, S., Sitaraman, S. V., Knight, R., Ley, R. E., & Gewirtz, A. T. (2010) · Science · doi:10.1126/science.1179721 · Cited by 2,068
Microbial Influences in Inflammatory Bowel Diseases
Sartor, R. B. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.059 · Cited by 1,927
Kruis, W., Frič, P., Pokrotnieks, J., Lukáš, M., Fixa, B., Kaščák, M., Kamm, M. A., Weismueller, J., Beglinger, C., Stolte, M., et al. (2004) · Gut · doi:10.1136/gut.2003.037747 · Cited by 1,285 · cited 1×
“coli Nissle 1917 was found to be effective and equivalent to mesalazine in maintaining remission in UC [85].”
BackgroundProphylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial
Gionchetti, P., Rizzello, F., Helwig, U., Venturi, A., Lammers, K. M., Brigidi, P., Vitali, B., Poggioli, G., Miglioli, M., & Campieri, M. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00171-9 · Cited by 1,147
Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives
Joossens, M., Huys, G., Cnockaert, M., De Preter, V., Verbeke, K., Rutgeerts, P., Vandamme, P., & Vermeire, S. (2011) · Gut · doi:10.1136/gut.2010.223263 · Cited by 1,063
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002 · cited 1×
“Altered microbiota composition in colon cancer patients when compared to patients with normal colonoscopies and in patients with IBS compared to unaffected patients has also been demonstrated [5, 9].”
BackgroundEnteric dysbiosis associated with a mouse model of alcoholic liver disease
Yan, A. W., Fouts, D. E., Brandl, J., Stärkel, P., Torralba, M., Schott, E., Tsukamoto, H., Nelson, K. E., Brenner, D. A., & Schnabl, B. (2011) · Hepatology · doi:10.1002/hep.24018 · Cited by 791
The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review
Moayyedi, P., Ford, A. C., Talley, N. J., Cremonini, F., Foxx-Orenstein, A. E., Brandt, L. J., & Quigley, E. M. M. (2010) · Gut · doi:10.1136/gut.2008.167270 · Cited by 728 · cited 1×
“Recent trials using Bifidobacterium bifidum and Saccharomyces boulardii demonstrated improvement in clinical IBS symptoms and quality of life [78, 79], and several reviews of the evidence for the utility of probiotics in IBS have been published [80–82].”
ResultKarczewski, J., Troost, F. J., Konings, I., Dekker, J., Kleerebezem, M., Brummer, R.-J. M., & Wells, J. M. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00327.2009 · Cited by 676 · cited 1×
“This paper discusses progress in understanding how probiotics contribute to intestinal mucosal function, particularly in relation to antiinflammatory signaling pathways.”
BackgroundKhoruts, A., Dicksved, J., Jansson, J. K., & Sadowsky, M. J. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181c87e02 · Cited by 649 · cited 1×
“A recent study showed that fecal bacteriotherapy was effective in relief of clinical symptoms in a patient with recurrent CDAD and that this was accompanied by the repopulation of the diseased intestinal microbiota with beneficial species that were diminished pretreatment [75].”
BackgroundIntestinal permeability and the prediction of relapse in Crohn's disease
Wyatt, J., Vogelsang, H., Hübl, W., Waldhoer, T., & Lochs, H. (1993) · The Lancet · doi:10.1016/0140-6736(93)90882-h · Cited by 626
Mechanisms of action of probiotics: Recent advances
Ng, S. C., Hart, A. L., Kamm, M. A., Stagg, A. J., & Knight, S. C. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20602 · Cited by 596 · cited 1×
“Several barriers exist to advocating broad use of probiotics in clinical practice, not least of which is the considerable heterogeneity in the experimental designs with respect to species and strains of probiotics and the various animal models utilized [94].”
BackgroundSecreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function
Ewaschuk, J. B., Diaz, H., Meddings, L., Diederichs, B., Dmytrash, A., Backer, J., Looijer-van Langen, M., & Madsen, K. L. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90227.2008 · Cited by 590 · cited 1×
“This paper discusses progress in understanding how probiotics contribute to intestinal mucosal function, particularly in relation to antiinflammatory signaling pathways.”
BackgroundModulation of human dendritic cell phenotype and function by probiotic bacteria
Hart, A. L., Lammers, K., Brigidi, P., Vitali, B., Rizzello, F., Gionchetti, P., Campieri, M., Kamm, M. A., Knight, S. C., & Stagg, A. J. (2004) · Gut · doi:10.1136/gut.2003.037325 · Cited by 555 · cited 1×
“Different probiotics have been shown to exert both proinflammatory [98] and anti-inflammatory effects on dendritic cells [99].”
BackgroundSood, A., Midha, V., Makharia, G. K., Ahuja, V., Singal, D., Goswami, P., & Tandon, R. K. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.07.016 · Cited by 513 · cited 1×
“VSL#3 has been shown to be safe and effective in the treatment of acute mild to moderately active UC [83].”
BackgroundAnderson, R. C., Cookson, A. L., McNabb, W. C., Park, Z., McCann, M. J., Kelly, W. J., & Roy, N. C. (2010) · BMC Microbiology · doi:10.1186/1471-2180-10-316 · Cited by 510 · cited 1×
“This paper discusses progress in understanding how probiotics contribute to intestinal mucosal function, particularly in relation to antiinflammatory signaling pathways.”
BackgroundTursi, A., Brandimarte, G., Papa, A., Giglio, A., Elisei, W., Giorgetti, G. M., Forti, G., Morini, S., Hassan, C., Pistoia, M. A., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.218 · Cited by 489
Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity
Ukena, S. N., Singh, A., Dringenberg, U., Engelhardt, R., Seidler, U., Hansen, W., Bleich, A., Bruder, D., Franzke, A., Rogler, G., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001308 · Cited by 482 · cited 1×
“This paper discusses progress in understanding how probiotics contribute to intestinal mucosal function, particularly in relation to antiinflammatory signaling pathways.”
BackgroundSeth, A., Yan, F., Polk, D. B., & Rao, R. K. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00202.2007 · Cited by 404
Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease
Conte, M. P., Schippa, S., Zamboni, I., Penta, M., Chiarini, F., Seganti, L., Osborn, J., Falconieri, P., Borrelli, O., & Cucchiara, S. (2006) · Gut · doi:10.1136/gut.2005.078824 · Cited by 383
Altered early infant gut microbiota in children developing allergy up to 5 years of age
Sjögren, Y. M., Jenmalm, M. C., Böttcher, M. F., Björkstén, B., & Sverremark‐Ekström, E. (2009) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2008.03156.x · Cited by 378 · cited 1×
“Decreased diversity of the intestinal microbiota was seen in fecal samples obtained from children who subsequently developed allergic disease [6, 7].”
BackgroundFernandez, E. M., Valenti, V., Rockel, C., Hermann, C., Pot, B., Boneca, I. G., & Grangette, C. (2011) · Gut · doi:10.1136/gut.2010.232918 · Cited by 376 · cited 2×
“A recent study demonstrated that the antiinflammatory effect of certain lactobacilli is via NOD2mediated signaling [100].”
BackgroundThe Utility of Probiotics in the Treatment of Irritable Bowel Syndrome: A Systematic Review
Brenner, D. M., Moeller, M. J., Chey, W. D., & Schoenfeld, P. S. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.25 · Cited by 362 · cited 1×
“Recent trials using Bifidobacterium bifidum and Saccharomyces boulardii demonstrated improvement in clinical IBS symptoms and quality of life [78, 79], and several reviews of the evidence for the utility of probiotics in IBS have been published [80–82].”
ResultGao, X. W., Mubasher, M., Fang, C. Y., Reifer, C., & Miller, L. E. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.11 · Cited by 318
Guglielmetti, S., Mora, D., Gschwender, M., & Popp, K. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04633.x · Cited by 287
A Randomized Controlled Trial of Lactobacillus GG in Children With Functional Abdominal Pain
Francavilla, R., Miniello, V., Magistà, A. M., De Canio, A., Bucci, N., Gagliardi, F., Lionetti, E., Castellaneta, S., Polimeno, L., Peccarisi, L., et al. (2010) · Pediatrics · doi:10.1542/peds.2010-0467 · Cited by 242
Choi, C. H., Jo, S. Y., Park, H. J., Chang, S. K., Byeon, J.-S., & Myung, S.-J. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e318204593e · Cited by 144
Russell, G., Kaplan, J., Ferraro, M., & Michelow, I. C. (2010) · PEDIATRICS · doi:10.1542/peds.2009-3363 · Cited by 120 · cited 1×
“Infusion of stool via nasogastric tube to the small intestine or via colonoscopy to the colon for CDAD has also been described and shows high response rates [71–74].”
Cited by
Gut Microbiota, Immune System, and Bone
D’Amelio, P., & Sassi, F. (2018) · Calcified Tissue International · doi:10.1007/s00223-017-0331-y · Cited by 315
Oliva, S., Di Nardo, G., Ferrari, F., Mallardo, S., Rossi, P., Patrizi, G., Cucchiara, S., & Stronati, L. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04939.x · Cited by 280
Vahabnezhad, E., Mochon, A. B., Wozniak, L. J., & Ziring, D. A. (2013) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e318279abf0 · Cited by 156
The human microbiome and bile acid metabolism: Dysbiosis, dysmetabolism, disease and intervention
Jones, M. L., Martoni, C. J., Ganopolsky, J. G., Labbé, A., & Prakash, S. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.880420 · Cited by 150
Metadata
- Authors
- Yoon, S. S., & Sun, J.
- Venue
- Gastroenterology Research and Practice
- Publisher
- Wiley
- Published
- 2011
- Volume
- 2011
- Pages
- 1-16
- ISSN
- 1687-6121 (ISSN-L)
- 1687-630X
- OpenAlex
- W2043131385
- Cited by
- 66
- References
- 29
- FWCI
- 8.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.